Literature DB >> 29378172

Modeling Idiopathic Pulmonary Fibrosis in Humanized Severe Combined Immunodeficient Mice.

David M Habiel1, Milena S Espindola2, Ana L Coelho2, Cory M Hogaboam3.   

Abstract

Idiopathic pulmonary fibrosis (IPF) is a fibrotic lung disease of unknown etiopathogenesis with limited therapeutic options. IPF is characterized by an abundance of fibroblasts and loss of epithelial progenitors, which cumulates in unrelenting fibrotic lung remodeling and loss of normal oxygenation. IPF has been challenging to model in rodents; nonetheless, mouse models of lung fibrosis provide clues as to the natural progression of lung injury and remodeling, but many have not been useful in predicting efficacy of therapeutics in clinical IPF. We provide a detailed methodologic description of various iterations of humanized mouse models, initiated by the i.v. injection of cells from IPF lung biopsy or explants specimens into severe combined immunodeficiency (SCID)/beige or nonobese diabetic SCID γ mice. Unlike cells from normal lung samples, IPF cells promote persistent, nonresolving lung remodeling in SCID mice. Finally, we provide examples and discuss potential advantages and pitfalls of human-specific targeting approaches in a humanized SCID model of pulmonary fibrosis.
Copyright © 2018 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29378172      PMCID: PMC5954978          DOI: 10.1016/j.ajpath.2017.12.020

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  83 in total

1.  Chronic interstitial pulmonary fibrosis produced in hamsters by endotracheal bleomycin. Lung volumes, volume-pressure relations, carbon monoxide uptake, and arterial blood gas studied.

Authors:  G L Snider; B R Celli; R H Goldstein; J J O'Brien; E C Lucey
Journal:  Am Rev Respir Dis       Date:  1978-02

Review 2.  Smoking-related idiopathic interstitial pneumonia: A review.

Authors:  George A Margaritopoulos; Sergio Harari; Antonella Caminati; Katerina M Antoniou
Journal:  Respirology       Date:  2015-07-02       Impact factor: 6.424

3.  Chronic obstructive pulmonary disease is associated with the -1055 IL-13 promoter polymorphism.

Authors:  T C T M van der Pouw Kraan; M Küçükaycan; A M Bakker; J M C Baggen; J S van der Zee; M A Dentener; E F M Wouters; C L Verweij
Journal:  Genes Immun       Date:  2002-11       Impact factor: 2.676

4.  Silicosis in mice: effects of dose, time, and genetic strain.

Authors:  G S Davis; K O Leslie; D R Hemenway
Journal:  J Environ Pathol Toxicol Oncol       Date:  1998       Impact factor: 3.567

Review 5.  Therapeutic targeting of IL-4- and IL-13-responsive cells in pulmonary fibrosis.

Authors:  Claudia Jakubzick; Steven L Kunkel; Raj K Puri; Cory M Hogaboam
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

Review 6.  Murine models of pulmonary fibrosis.

Authors:  Bethany B Moore; Cory M Hogaboam
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2007-11-09       Impact factor: 5.464

7.  Fibrosis of two: Epithelial cell-fibroblast interactions in pulmonary fibrosis.

Authors:  Norihiko Sakai; Andrew M Tager
Journal:  Biochim Biophys Acta       Date:  2013-03-14

8.  Telomerase and telomere length in pulmonary fibrosis.

Authors:  Tianju Liu; Matthew Ullenbruch; Yoon Young Choi; Hongfeng Yu; Lin Ding; Antoni Xaubet; Javier Pereda; Carol A Feghali-Bostwick; Peter B Bitterman; Craig A Henke; Annie Pardo; Moises Selman; Sem H Phan
Journal:  Am J Respir Cell Mol Biol       Date:  2013-08       Impact factor: 6.914

9.  Conditional expression of transforming growth factor-alpha in adult mouse lung causes pulmonary fibrosis.

Authors:  William D Hardie; Timothy D Le Cras; Kenny Jiang; Jay W Tichelaar; Mohamad Azhar; Thomas R Korfhagen
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2003-12-05       Impact factor: 5.464

10.  Inverse association of plasma IL-13 and inflammatory chemokines with lung function impairment in stable COPD: a cross-sectional cohort study.

Authors:  Janet S Lee; Matthew R Rosengart; Venkateswarlu Kondragunta; Yingze Zhang; Jessica McMurray; Robert A Branch; Augustine M K Choi; Frank C Sciurba
Journal:  Respir Res       Date:  2007-09-14
View more
  10 in total

1.  Reply to D'Alessandro-Gabazza et al.: Risks of Treating Idiopathic Pulmonary Fibrosis with a TAM Receptor Kinase Inhibitor.

Authors:  Milena S Espindola; David M Habiel; Cory M Hogaboam
Journal:  Am J Respir Crit Care Med       Date:  2018-10-01       Impact factor: 21.405

2.  CCR10+ epithelial cells from idiopathic pulmonary fibrosis lungs drive remodeling.

Authors:  David M Habiel; Milena S Espindola; Isabelle C Jones; Ana Lucia Coelho; Barry Stripp; Cory M Hogaboam
Journal:  JCI Insight       Date:  2018-08-23

3.  Bleomycin Induces Drug Efflux in Lungs. A Pitfall for Pharmacological Studies of Pulmonary Fibrosis.

Authors:  Joshua K Park; Nathan J Coffey; Steven P Bodine; Charles N Zawatsky; Lindsey Jay; William A Gahl; George Kunos; Bernadette R Gochuico; May Christine V Malicdan; Resat Cinar
Journal:  Am J Respir Cell Mol Biol       Date:  2020-02       Impact factor: 6.914

4.  Interleukin-13 disrupts type 2 pneumocyte stem cell activity.

Authors:  Kristen M Glisinski; Adam J Schlobohm; Sarah V Paramore; Anastasiya Birukova; M Arthur Moseley; Matthew W Foster; Christina E Barkauskas
Journal:  JCI Insight       Date:  2020-01-16

5.  Targeting MAP3K19 prevents human lung myofibroblast activation both in vitro and in a humanized SCID model of idiopathic pulmonary fibrosis.

Authors:  Isabelle C Jones; Milena S Espindola; Rohan Narayanan; Ana L Coelho; David M Habiel; Stefen A Boehme; Tai Wei Ly; Kevin B Bacon; Cory M Hogaboam
Journal:  Sci Rep       Date:  2019-12-24       Impact factor: 4.379

Review 6.  Lung Organoids-The Ultimate Tool to Dissect Pulmonary Diseases?

Authors:  Veronika Bosáková; Marco De Zuani; Lucie Sládková; Zuzana Garlíková; Shyam Sushama Jose; Teresa Zelante; Marcela Hortová Kohoutková; Jan Frič
Journal:  Front Cell Dev Biol       Date:  2022-07-13

7.  Differential Responses to Targeting Matrix Metalloproteinase 9 in Idiopathic Pulmonary Fibrosis.

Authors:  Milena S Espindola; David M Habiel; Ana Lucia Coelho; Barry Stripp; William C Parks; Justin Oldham; Fernando J Martinez; Imre Noth; David Lopez; Amanda Mikels-Vigdal; Victoria Smith; Cory M Hogaboam
Journal:  Am J Respir Crit Care Med       Date:  2021-02-15       Impact factor: 21.405

8.  Antibody-mediated depletion of CCR10+EphA3+ cells ameliorates fibrosis in IPF.

Authors:  Miriam S Hohmann; David M Habiel; Milena S Espindola; Guanling Huang; Isabelle Jones; Rohan Narayanan; Ana Lucia Coelho; Justin M Oldham; Imre Noth; Shwu-Fan Ma; Adrianne Kurkciyan; Jonathan L McQualter; Gianni Carraro; Barry Stripp; Peter Chen; Dianhua Jiang; Paul W Noble; William Parks; John Woronicz; Geoffrey Yarranton; Lynne A Murray; Cory M Hogaboam
Journal:  JCI Insight       Date:  2021-06-08

9.  One Molecule, Two Opposite Biological Effects: The Many Faces of Matrix Metalloproteases in the Pathogenesis of Idiopathic Pulmonary Fibrosis.

Authors:  Annie Pardo; Moises Selman
Journal:  Am J Respir Crit Care Med       Date:  2021-02-15       Impact factor: 21.405

Review 10.  The perplexing role of RAGE in pulmonary fibrosis: causality or casualty?

Authors:  Timothy N Perkins; Tim D Oury
Journal:  Ther Adv Respir Dis       Date:  2021 Jan-Dec       Impact factor: 4.031

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.